| Symbol | CRSP |
|---|---|
| Name | CRISPR THERAPEUTICS AG |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | BAARERSTRASSE 14, ZUG, 6300, Switzerland |
| Telephone | +41 41 - 561 32 77 |
| Fax | — |
| — | |
| Website | https://www.crisprtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001674416 |
| Description | CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPRs most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes. Additional info from NASDAQ: |
(30% Negative) CRISPR THERAPEUTICS AG (CRSP) Reports Q3 2026 Financial Results
Read moreCRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Read moreNew Form SCHEDULE 13G/A - CRISPR Therapeutics AG <b>Filed:</b> 2026-07-27 <b>AccNo:</b> 0002012383-26-002146 <b>Size:</b> 11 KB
Read moreGeorge Simeon 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264390
Read moreBehbahani Ali 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264382
Read moreFardis Maria 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264290
Read moreFleming Harold Edward 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264289
Read moreGreene John 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264288
Read moreHigh Katherine A 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264287
Read moreMahatme Sandesh 🟢 acquired 13.0K shares (1 derivative) of CRISPR Therapeutics AG (CRSP) at $51.84 Transaction Date: Jun 05, 2026 | Filing ID: 264286
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07549698 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/R… | Phase1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | Recruiting | 2026-06-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT07549698 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/R… | Phase1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | Recruiting | 2026-06-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT06907875 | A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Phase1 | Facioscapulohumeral Muscular Dystrophy | Active_Not_Recruiting | 2025-05-08 | 2032-04-30 | ClinicalTrials.gov |
| NCT06907875 | A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Phase1 | Facioscapulohumeral Muscular Dystrophy | Active_Not_Recruiting | 2025-05-08 | 2032-04-30 | ClinicalTrials.gov |
| NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory… | Phase1 | SLE (Systemic Lupus) | Recruiting | 2025-03-10 | 2031-12-31 | ClinicalTrials.gov |
| NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory… | Phase1 | SLE (Systemic Lupus) | Recruiting | 2025-03-10 | 2031-12-31 | ClinicalTrials.gov |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/R… | Phase1 | T Cell Lymphoma | Completed | 2024-08-13 | 2026-03-11 | ClinicalTrials.gov |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/R… | Phase1 | T Cell Lymphoma | Completed | 2024-08-13 | 2026-03-11 | ClinicalTrials.gov |
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refracto… | Phase1 | Cardiovascular | Recruiting | 2024-06-21 | 2028-06-01 | ClinicalTrials.gov |
| NCT07491172 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refracto… | Phase1 | Cardiovascular | Recruiting | 2024-06-21 | 2028-06-01 | ClinicalTrials.gov |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Ther… | — | Hematologic Malignancy | Enrolling_By_Invitation | 2023-11-22 | 2038-08-01 | ClinicalTrials.gov |
| NCT06208878 | A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Ther… | — | Hematologic Malignancy | Enrolling_By_Invitation | 2023-11-22 | 2038-08-01 | ClinicalTrials.gov |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed o… | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2023-03-13 | 2025-09-18 | ClinicalTrials.gov |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed o… | Phase1 | Clear Cell Renal Cell Carcinoma | Completed | 2023-03-13 | 2025-09-18 | ClinicalTrials.gov |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refr… | Phase1 | B-cell Lymphoma | Recruiting | 2023-03-10 | 2030-02-01 | ClinicalTrials.gov |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refr… | Phase1 | B-cell Lymphoma | Recruiting | 2023-03-10 | 2030-02-01 | ClinicalTrials.gov |
| NCT05565248 | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of V… | Phase1 | Diabetes Mellitus | Terminated | 2023-01-20 | 2025-08-08 | ClinicalTrials.gov |
| NCT05565248 | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of V… | Phase1 | Diabetes Mellitus | Terminated | 2023-01-20 | 2025-08-08 | ClinicalTrials.gov |
| NCT05210530 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Com… | Phase1 | Diabetes Mellitus | Completed | 2022-01-24 | 2023-01-19 | ClinicalTrials.gov |
| NCT05210530 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Com… | Phase1 | Diabetes Mellitus | Completed | 2022-01-24 | 2023-01-19 | ClinicalTrials.gov |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | T Cell Lymphoma | Terminated | 2020-07-31 | 2024-08-30 | ClinicalTrials.gov |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | T Cell Lymphoma | Terminated | 2020-07-31 | 2024-08-30 | ClinicalTrials.gov |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | Renal Cell Carcinoma | Terminated | 2020-06-16 | 2024-10-08 | ClinicalTrials.gov |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refr… | Phase1 | Renal Cell Carcinoma | Terminated | 2020-06-16 | 2024-10-08 | ClinicalTrials.gov |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refr… | Phase1 | Multiple Myeloma | Terminated | 2020-01-22 | 2024-01-04 | ClinicalTrials.gov |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refr… | Phase1 | Multiple Myeloma | Terminated | 2020-01-22 | 2024-01-04 | ClinicalTrials.gov |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refr… | Phase1 | B-cell Malignancy | Terminated | 2019-07-22 | 2024-10-04 | ClinicalTrials.gov |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refr… | Phase1 | B-cell Malignancy | Terminated | 2019-07-22 | 2024-10-04 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX112 | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06925542 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | RECRUITING | NCT07549698 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT06907875 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06925542 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | RECRUITING | NCT07549698 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT05565248 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT05565248 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT05565248 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT05565248 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | TERMINATED | NCT05565248 |
| VCTX210A unit | Other | Phase PHASE1 | Diabetes Mellitus | COMPLETED | NCT05210530 |
| VCTX211 | Other | Phase PHASE1 | Diabetes Mellitus | RECRUITING | NCT05565248 |
| CTX130 | Other | Phase PHASE1 | T Cell Lymphoma | TERMINATED | NCT04502446 |
| CTX130 | Other | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT04438083 |
| CTX120 | Other | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT04244656 |
| Non Interventional | Other | Preclinical | Hematologic Malignancy | ENROLLING_BY_INVITATION | NCT06208878 |
| CTX110 | Other | Phase PHASE1 | B-cell Malignancy | TERMINATED | NCT04035434 |
| CTX112 | Other | Phase PHASE1 | B-cell Lymphoma | RECRUITING | NCT05643742 |
| CTX131 | Other | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT05795595 |
| CTX112 | Other | Phase PHASE1 | SLE (Systemic Lupus) | RECRUITING | NCT06925542 |
| CTX310 | Other | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| CTX131 | Other | Phase PHASE1 | T Cell Lymphoma | COMPLETED | NCT06492304 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| CTX112 | Other | Phase PHASE1 | Warm Autoimmune Hemolytic Anemia (WAIHA) | NOT_YET_RECRUITING | NCT07549698 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | Other | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| EPI-321 | BIOLOGICAL | Phase PHASE1 | Facioscapulohumeral Muscular Dystrophy | RECRUITING | NCT06907875 |
| CTX310 | DRUG | Phase PHASE1 | Cardiovascular | RECRUITING | NCT07491172 |
| Non Interventional | OTHER | Preclinical | Hematologic Malignancy | ENROLLING_BY_INVITATION | NCT06208878 |
| CTX131 | BIOLOGICAL | Phase PHASE1 | Clear Cell Renal Cell Carcinoma | COMPLETED | NCT05795595 |
| CTX112 | BIOLOGICAL | Phase PHASE1 | B-cell Lymphoma | RECRUITING | NCT05643742 |
| CTX130 | BIOLOGICAL | Phase PHASE1 | T Cell Lymphoma | TERMINATED | NCT04502446 |
| CTX120 | BIOLOGICAL | Phase PHASE1 | Multiple Myeloma | TERMINATED | NCT04244656 |
| CTX110 | BIOLOGICAL | Phase PHASE1 | B-cell Malignancy | TERMINATED | NCT04035434 |